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Summary
To understand the role of human epidermal growth factor receptor (hEGFR) kinase domain mutations in lung tumorigenesis
and response to EGFR-targeted therapies, we generated bitransgenicmicewith inducible expression in type II pneumocytes
of two common hEGFR mutants seen in human lung cancer. Both bitransgenic lines developed lung adenocarcinoma after
sustained hEGFR mutant expression, confirming their oncogenic potential. Maintenance of these lung tumors was depen-
dent on continued expression of the EGFR mutants. Treatment with small molecule inhibitors (erlotinib or HKI-272) as well
as prolonged treatment with a humanized anti-hEGFR antibody (cetuximab) led to dramatic tumor regression. These data
suggest that persistent EGFR signaling is required for tumor maintenance in human lung adenocarcinomas expressing
EGFR mutants.Introduction
EGFR is a tyrosine kinase receptor that plays an integral part
in signaling pathways that control normal and malignant cell
growth (Arteaga, 2003; Hynes and Lane, 2005). Because
EGFR is overexpressed in many different tumor types, including
more than 80% of non-small cell lung cancers (NSCLC), it was
one of the first molecules to be selected for the development
of targeted therapies (Hynes and Lane, 2005; Janne et al.,
2005; Minna et al., 2005). However, it remains unclear whether
overexpression of EGFR plays a crucial role in the malignant
transformation of various cell types or is merely a secondary
consequence of a selection process for growth advantage after
tumor initiation. For EGFR-targeted therapy to be effective, theCANCER CELL 9, 485–495, JUNE 2006 ª2006 ELSEVIER INC. DOI 10.101targeted tumor should ideally depend on EGFR activity for its
malignant transformation and survival. Thus, the difference
seen in the effectiveness of EGFR-targeted therapy in NSCLC
patients with different EGFR status might be due to the hetero-
geneous roles that EGFR plays in the development of individual
tumors.
Small molecule inhibitors of the EGFR enzymatic activity and
antibodies against EGFR are the two major classes of agents
that have been developed and used clinically for the treatment
of cancers known to express EGFR (Giaccone, 2005; Hynes
and Lane, 2005). While monoclonal antibodies such as cetuxi-
mab were designed to interfere with the binding of ligands to
the hEGFR extracellular domain and to block downstream sig-
naling, small molecules, including either reversible inhibitorsS I G N I F I C A N C E
The somatic hEGFR kinasedomainmutations are highly correlatedwith the clinical response to gefitinib or erlotinib therapy in lung can-
cer patients. Our findings that these hEGFR kinase domain mutants are oncogenic in vivo and that their continual expression is neces-
sary for tumor maintenance validate the importance of the mutated enzyme as a therapeutic target. EGFR-targeted therapy against
murine cancers overexpressing hEGFR mutants is dramatically effective, suggesting that these mutants are directly involved in tumor
maintenance. These inducible mousemodels will be useful for evaluation of a new generation of EGFR inhibitors as well as other novel
therapeutics prior to human clinical trials.6/j.ccr.2006.04.022 485
A R T I C L Elike gefitinib and erlotinib or the irreversible inhibitor HKI-272
(Kwak et al., 2005; Rabindran et al., 2004), are intracellular tyro-
sine kinase enzymatic inhibitors (TKI) that disrupt the kinase ac-
tivity by binding the adenosine triphosphate (ATP) pocket within
the catalytic domain (Giaccone, 2005; Hynes and Lane, 2005).
Although the overall response rate of NSCLC patients to small
molecule EGFR inhibitors was only 10% to 20% in several large
clinical trials, somatic mutations in the kinase domain of hEGFR
gene in NSCLC patients were subsequently found to be highly
correlated with sensitivity (>80%) to gefitinib and erlotinib ther-
apy (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004).
Emerging data also suggest that increased EGFR copy num-
ber is a predictor of response to gefitinib therapy, regardless of
hEGFR kinase domain mutational status (Cappuzzo et al.,
2005a). Increased copy number of hEGFR, however, was ob-
served more frequently in patients bearing hEGFR mutations
than in patients with wild-type (wt) EGFR (56% versus 22%),
suggesting that the mutant alleles are selectively amplified. A
similar finding has been observed in NSCLC cell lines (Gazdar
et al., 2004; Sordella et al., 2004; Suzuki et al., 2005; Takano
et al., 2005; Tracy et al., 2004). These findings have been con-
strued to represent that the transformed cells exhibit an ‘‘onco-
gene addiction’’ to the EGFR mutants (Blagosklonny, 2004;
Gazdar et al., 2004). Furthermore, in contrast to wt hEGFR,
the hEGFR kinase domain mutations are mutually exclusive of
K-ras mutation (Pao et al., 2005b; Shigematsu et al., 2005a;
Soung et al., 2005). In addition, recent preclinical and clinical
data suggest that cetuximab is not as effective as gefitinib or er-
lotinib in treating patients with lung cancer whose tumors harbor
hEGFR kinase domainmutations (Mukohara et al., 2005; Tsuchi-
hashi et al., 2005). These studies support the conclusion that
hEGFR kinase domain mutants may have a different role in a
tumor than wt hEGFR, the latter more likely being a secondary
event in cancer progression due to a growth advantage selec-
tion, while the former may play a causal role in malignant trans-
formation. A better understanding of the role of the hEGFR
kinase domain mutants in the tumor initiation and maintenance
in vivo will enhance our understanding and guide the use of
EGFR-targeted therapy in patients whose tumors harbor these
mutations.
Two of the most common kinase domain hEGFR mutations,
accounting for approximately 80% of all known mutations in
NSCLC, are the exon 19 deletion of the conserved four amino
acid sequence LREA and the L858R point mutation in exon
21(Pao and Miller, 2005; Shigematsu et al., 2005a; Shigematsu
et al., 2005b). In vitro studies using NIH3T3 and Ba/F3 cells
showed that these hEGFR kinase domain mutants are trans-
forming and confer sensitivity of these transformed cells to
gefitinib and erlotinib growth inhibition (Greulich et al., 2005;
Kobayashi et al., 2005b). Furthermore, most of the NSCLC cell
lines harboring the hEGFR kinase domain mutations are highly
sensitive to gefitinib or erlotinib (Amann et al., 2005; Paez
et al., 2004; Tracy et al., 2004). Retrospective studies have dem-
onstrated that NSCLC patients harboring the hEGFR kinase do-
main mutations treated with gefitinib have a significantly greater
response (89%) and longer survival compared to those with wt
EGFR (Mitsudomi et al., 2005; Takano et al., 2005). However,
the precise roles these hEGFR kinase domain mutations play
in the initiation, progression, and maintenance of NSCLC in
vivo remains unclear. Additionally, the importance of these mu-
tations in predicting response to EGFR-targeted therapies such486as small molecule inhibitors andmonoclonal antibodies remains
a clinically important but unanswered question.
To this end, we generated inducible bitransgenicmice that ex-
press the two common hEGFR kinase domainmutants, the exon
19 deletion of the conserved region including LREA (referred to
as Del) and the exon 21 substitution point mutation L858R. The
expression of these two hEGFR mutants was targeted to lung
type II pneumocytes using the CCSP-rtTA allele (Fisher et al.,
2001). We demonstrated that the expression of either hEGFR
mutant in the lungs of these bitransgenic mice is sufficient for
the development of adenocarcinoma with bronchioloalveolar
carcinoma (BAC) features. The histopathologic features of mu-
rine lung tumors were similar to features present in tumors
from NSCLC patients harboring these hEGFR kinase domain
mutations. Deinduction of the hEGFR mutant expression in es-
tablished adenocarcinomas caused tumor regression, demon-
strating that the activated EGFR pathway was necessary for
tumor maintenance. Lastly, these lung tumors driven by the
expression of hEGFR kinase domain mutants dramatically re-
sponded to the small molecule EGFR inhibitors erlotinib and
HKI-272 as well as more prolonged treatment with the monoclo-
nal anti-hEGFR antibody, cetuximab.
Results
Generation of Tet-op-hEGFR L858R-Luc
and Tet-op-hEGFR Del-Luc alleles
To generate mice with inducible expression of two common
hEGFR mutants, an exon 19 deletion mutant (Del) and exon 21
L858R mutant (L858R) in murine lung epithelial cells, we con-
structed a 6.0 kb DNA segment consisting of seven direct
repeats of the tetracycline (tet)-operator sequence, an hEGFR
L858R or hEGFR Del cDNA, and internal ribosome entry site
(IRES) followed by luciferase cDNA and the SV40 poly (A)
(Figure S1A in the Supplemental Data available with this article
online, and Experimental Procedures). Expression of the lucifer-
ase protein linked to IRES allowed us to monitor the concurrent
expression of hEGFR mutants in the affected cell populations
through in vivo noninvasive imaging. These constructs were in-
jected into FVB/N blastocysts and the progeny was screened
using Southern blot and PCR strategy (data not shown). Eight
hEGFR L858R founders and 12 hEGFR Del founders, referred
to as Tet-op-hEGFR L858R-Luc and Tet-op-hEGFRDel-Luc, re-
spectively, were identified from these analyses and then
crossed to Clara cell secretory protein (CCSP)-rtTA mice, har-
boring an allele that had been shown specifically to target the
expression of the reverse tetracycline transactivator protein
(rtTA) in type II alveolar epithelial cells (Fisher et al., 2001; Perl
et al., 2002). This allowed us to generate bitransgenic mouse co-
horts harboring both the activator and the responder transgenes
to test the inducibility of the transgene with doxycycline admin-
istration (Fisher et al., 2001; Perl et al., 2002). Two tightly induc-
ible hEGFR Del (#19 and #23) founders and three hEGFR L858R
founders (#12, #14, and #27) were identified by RT-PCR analy-
sis, with low or no baseline expression of transgene that can
be induced up to 10-fold after 2 weeks of doxycycline adminis-
tration (see below). Additionally, the copy numbers from individ-
ual founders were determined by quantitative real-time PCR
(Figure S1B). The Del (#19 and #23) founders and L858R
founders (#14 and #27) with similar transgene copy numbers
were chosen for the following experiments.CANCER CELL JUNE 2006
A R T I C L EInducibility of both hEGFR mutants L858R and Del
in lung tissues
The inducibility of the two human EGFR kinase domain mutant
transgenes was evaluated in the lungs at both RNA and protein
levels. RT-PCR with transgene-specific primers was performed
to determine the hEGFRmutant RNA level in the lungs of the bi-
transgenic mouse CCSP-rtTA/Tet-op-hEGFR L858R-Luc and
CCSP-rtTA/Tet-op-hEGFR Del-Luc cohorts for each potential
founder before and after 2 weeks of doxycycline administration.
All mice had normal lung histology (data not shown). The hEGFR
mutant transcripts were undetectable from both nontransgenic
and the bitransgenic mice without doxycycline treatment, but
readily detectable after 2 weeks of doxycycline administration
in both Del and L858R mice lines (Figure 1A). To confirm that
the induction of hEGFR mutants also occured at the protein
level, immunoblotting was performed on lung lysates from the
bitransgenic mice before and after doxycycline administration.
Typical induction in total EGFR protein levels was shown from
bitransgenic mice from both theDel and L858R lines (Figure 1B).
This subsequently led to the activation of EGFR by the phos-
phorylation of three important tyrosine residues, 992, 1068,
and 1173, which are associated with both cell proliferation and
survival signaling (Figure 1B) (Sordella et al., 2004). Since normal
lungs express a fairly low level of mouse endogenous EGFR, no
phosphorylation of EGFR was observed in nontransgenic wt
mice (Figure 1B). Therefore, the EGFR phosphorylation and ac-
tivation most likely resulted from the induction of hEGFR kinase
domain mutant expression.
To further confirm the in vivo induction of the transgenes, we
took advantage of the noninvasive bioluminescent imaging to
detect the activity of coexpressed luciferase (Zhang et al.,
2004). The bitransgenic mice from both L858R and Del lines (3
each group) were imaged on day 1 before doxycycline adminis-
tration to confirm the lack of luciferase expression at baseline
(Figure S2A). After 5 days of doxycycline administration, these
mice showed high luciferase activity specifically over the re-
gions of the lungs, indicating the tissue-specific induction of
hEGFR mutants (Figure S2B). Withdrawal of doxycycline from
the diet was started on day 5, and these mice were then subse-
quently imaged on days 6, 8, and 10. The luciferase activity rap-
idly declined on day 6 after 1 day of doxycycline withdrawal, and
completely disappeared on day 10 (Figures S2C–S2E). Corre-
spondingly, we showed an extinction of hEGFR mutant expres-
sion with similar kinetics upon doxycycline withdrawal (see be-
low). Thus, these data support the specific expression of the
transgenes in the lung and their temporal regulation by doxycy-
cline administration.
Overexpression of the hEGFR L858R and hEGFR Del
mutants drive initiation and progression of the lung
adenocarcinoma with BAC features
To determine if overexpression of the hEGFR kinase domain
mutants can initiate lung tumorigenesis, bitransgenic mice
from both the L858R andDel cohorts on continuous doxycycline
administration were sacrificed at various time points for histo-
logical examination of the lungs. In contrast to the normal histol-
ogy in untreated mice (Figure 2A), early precancerous atypical
adenomatous hyperplasia (AAH) lesions started to appear after
3–4weeks of doxycycline treatment (Figure 2B). After 5–6weeks
of continuous doxycycline administration, multiple tumor foci of
BACwere present in both lungs of bitransgenicmice (Figure 2C).CANCER CELL JUNE 2006Tumors diffusely involved the lung parenchyma, the peripheral
spaces surrounding the airways and the subpleural regions
(Figure 2C). Benign adenoma was also notable at this stage
(Figure 2D). Invasive adenocarcinomas with acinar, papillary,
and solid features were present after 8–10 weeks (Figure 2E).
The tumors were positive for phospho-EGFR Y1068, indicating
that the induction of hEGFR mutants leads to the activation of
EGFR signaling (Figure 2F). This EGFR activation is accompa-
nied with phosphorylation and activation of downstream signal-
ing molecules, including Erk1/2 (Figure 2G) and Akt (Figure 2H).
Tumors driven by the expression of these hEGFR kinase
domain mutants stained positive for prosurfactant protein C
(SP-C) (Figure 2I) but negative for the Clara cell marker CCSP
(Figure 2J). Although these data suggest a type II pneumocyte
tumor cell origin, it is also possible that these tumors initiated
from progenitor/stem cells located in the terminal airways that
are double-positive for CCSP and SPC, with the ability to differ-
entiate into single-positive cells dependent on the location (Kim
et al., 2005). None of the monotransgenic hEGFR mutant mice
(>5 mice in each cohort) from both lines (L858R #27 and Del
#19) and the CCSP-rtTA monotransgenic mice (5 mice) devel-
oped lung tumors or other lung pathological changes despite
doxycycline administration for up to 32 weeks. These data con-
firm the nonleakiness of the bitransgenic regulatory system in
these founders and that doxycycline exposure does not play
a crucial role in lung tumorigenesis in our system (Seftor et al.,
Figure 1. Induction of hEGFR kinase domain mutants at both RNA and pro-
tein levels in bitransgenic mice from different founders of L858R and Del lines
A: Bitransgenic mice from indicated lines were divided into two groups and
given a diet with or without doxycycline. After 2 weeks of doxycycline treat-
ment, the transcriptional levels of hEGFR mutants in the lungs from these two
groups were evaluated by RT-PCR, as described in the Experimental Proce-
dures.
B: Protein levels of both mouse and human total EGFR as well as phosphor-
ylated EGFR at different tyrosine residues were analyzed by immunoblotting.
b-actin serves as loading control. Representative data are shown from three
independent experiments.487
A R T I C L EFigure 2. Expression of hEGFR mutants leads to the development of lung adenocarcinoma with BAC feature
A: Representative photomicrographs of a cross-sectional view from the L858R line of mouse lung illustrating histopathologic assessment of lung carcinoma.
At least 4 mice at each time point were examined for histology. Bitransgenic mice up to 30 weeks old without doxycycline treatment have normal histopath-
ologic features.
B: Early precancerous AAH lesions started to appear after 3 to 4 weeks of doxycycline treatment.
C and D: Multiple tumor foci of BAC (C) and benign adenoma (D) are present after 5–6 weeks of continuous doxycycline administration.
E: Invasive adenocarcinoma appears after 8 or more weeks of continuous doxycycline treatment.
F–H: Tumors are positive for phospho-EGFR (F), stained in blue/gray, associated with downstream activation of Erk1/2 (G) and Akt (H), stained in brown.
I and J: The tumors are positive for SPC staining (I) but negative for CCSP staining (J).1998). Bitransgenic mice from the two founders of the hEGFR
Del allele (#19 and #23) and three founders of the hEGFR
L858R allele (#12, #14, and #27) all developed indistinguishable
adenocarcinoma with BAC features after 8 or more weeks of
sustained doxycycline induction (data not shown).
The induction of hEGFRmutant in the lungs in the bitransgenic
mice as a function of time on doxycycline treatment was further
analyzed molecularly at both RNA and protein levels (Figure 3).
In both L858R and Del bitransgenic lines, the hEGFR transcripts
appeared after 2 weeks of doxycycline treatment and increased
with time for 8 or more weeks of doxycycline treatment (Fig-
ure 3A). This was further confirmed by quantitative real-time
RT-PCR. After 2 weeks of doxycycline treatment, a significant
increase of total human andmouse EGFRmRNAwas observed,
approximately 8-fold in the L858R line (#27) and 10-fold in the
Del line (#19) (Figure 3B). Continuous doxycycline treatment
for 8 or more weeks was accompanied by even higher EGFR
levels, with a 32-fold increase in L858R line and a 77-fold in-
crease in Del line (Figure 3B). This increase in expression likely
represents an accumulation of EGFR mutant-expressing cells
at the later time point, rather than increased expression of the
transgene on a per-cell basis. Consistent with this observation,
total EGFR protein level increased with time on doxycycline
treatment (Figure 3C), which was associated with an increase
in EGFR phosphorylation and activation of the downstream sig-
naling molecules Akt and Erk1/2 (Figure 3C). A baseline level of
phospho-Akt and phospho-Erk1/2 in the lungs from either nor-
mal wt or single transgenic mice or the bitransgenic mice488without doxycycline administration was consistently observed.
Sequencing analyses of these lung tumors showed that they
are wild-type for K-ras, and real-time PCR data demonstrated
that there was no amplification of the hEGFR mutant transgene
or the mouse endogenous EGFR locus during the process of
tumorigenesis (data not shown). No difference in the EGF and
TGF-a transcript levels in the lungs from bitransgenic mice be-
fore and after sustained doxycycline administration was ob-
served (data not shown), although it remains formally possible
that other EGFR ligands such as amphiregulin, HB-EGF, or be-
tacellulinmight be differentially affected (Hynes and Lane, 2005).
These data indicate that overexpression of EGFR mutant driven
by the high copy of transgenes itself may be sufficient to drive
lung tumorigenesis and progression.
Expression of the hEGFR mutants is essential
for tumor maintenance
To determine whether the continued expression of hEGFR ki-
nase domain mutants is required for tumor maintenance and
cell survival, doxycycline was withdrawn from the diet of tu-
mor-bearing mice to deinduce the mutated hEGFR transgene
expression. These tumor-bearing mice were serially analyzed
molecularly, radiographically, and histopathologically before
and after doxycycline withdrawal. RT-PCR was performed to
determine the hEGFR kinase domain mutant expression level
on the pathologic lungs of bitransgenic mouse cohorts on doxy-
cyclinewith tumors and after doxycyclinewithdrawal. After with-
drawal of doxycycline from the diet for only 3 days, the hEGFRCANCER CELL JUNE 2006
A R T I C L EFigure 3. Molecular analysis of the induction of
hEGFR kinase domain mutants with time on
doxycycline administration and activation of
downstream signaling
A: Induction and deinduction of hEGFR kinase
domain mutant mRNA transcript by feeding the
bitransgenic mice a diet with or without doxycy-
cline as indicated. b-actin transcriptional level
serves as negative control.
B:Quantitative RT-PCR analysis of total EGFR tran-
script induction and deinduction in bitransgenic
mice from both L858RandDel lines. Each sample
was amplified in triplicate for detection of both
total EGFR and b-actin transcripts. The endoge-
nous mouse EGFR level from nontransgenic
mice was arbitrarily designated as 1 and used
to derive the standard curve. Data were ana-
lyzed by relative quantitation using the compar-
ative Ct method and normalization to b-actin,
and error bars correspond to mean 6 standard
deviation. Statistical analyses were preformed
using Student’s exact t test.
C: Bitransgenic mice from Del lines were treated
with doxycycline for the indicated time, and lung
lysates were subjected to immunoblotting for total
EGFR, phospho-EGFR, and downstream phospho-
Akt and phospho-Erk1/2 protein levels. b-actin
serves as loading control. Representative data
are shown from three independent experiments.mutant RNA levels in the lungs from both two lines returned to
levels similar to those from untreated control mice (Figure 3A).
This deinduction of expression was further confirmed by quan-
titative real-time RT-PCR (Figure 3B).
To demonstrate that continued hEGFR kinase domain mutant
expression is necessary for lung tumor maintenance, bitrans-
genic CCSP-rtTA/Tet-op-L858R-Luc and CCSP-rtTA/Tet-op-
Del-Luc mice (4 mice per group) treated with 8 weeks doxycy-
cline were imaged with a baseline MRI scan to document the
lung tumor burden in each mouse. Doxycycline was then re-
moved from the diet for 1 week, and animals were then sub-
jected to MRI reimaging. In all these mice, the lung tumors con-
sistently regressed dramatically (with a decrease of 93.4% 6
2.9% in the Del line and 91.3% 6 2.1% in the L858R line) as
documented by MRI (Figure 4A). These observations estab-
lished the essential role of persistent expression of hEGFR mu-
tants on lung tumor maintenance. To test if tumors recur after
complete regression, we performed the long-term doxycycline
withdrawal experiments. After 3 weeks of doxycycline with-
drawal, a complete regression of the lung tumors was observed
(Figure 4B), and there were no tumor recurrences with an addi-
tional 6 weeks of doxycycline withdrawal (Figure 4B). This fur-
ther confirms the essential role of EGFR mutant expression in
lung tumor maintenance and validates EGFR mutants as good
targets for cancer therapies.
In comparison with the tumors from mice that remained on
doxycycline (Figure 5A), there was a dramatic decrease in tumor
density and cellularity after 1 week of doxycycline withdrawal
(Figure 5B). There were foci of mildly increased interstitial thick-
ness and cellularity that likely represented the remnants of the
tumors after doxycycline withdrawal (Figure 5B). These histo-
logic responses correlated with the MRI analysis of tumor re-
gression. No residual tumors were found in lungs from three bi-
transgenic mice after doxycycline was removed from the diet for
more than 3 weeks (Figure 5C). Concomitant with the rapid
tumor regression after 1 week of doxycycline withdrawal, weCANCER CELL JUNE 2006observed a 23-fold decrease of Ki-67-positive tumor cells (Fig-
ures 5D, 5E, and 5H). To determine if the tumor regression
was also associated with apoptosis, we performed TUNEL as-
says using tumor samples from bitransgenic mice before and
after doxycycline withdrawal (Figures 5F, 5G, and 5I). We noted
a 20-fold increase of TUNEL-positive cells after 1 week of doxy-
cycline withdrawal (Figure 5I). Consistent with this, Western blot
analyses using the whole lung lysate showed that after doxycy-
cline withdrawal, a dramatic reduction of both total EGFR and
activated EGFR levels was observed in the lungs of these bi-
transgenic mice (Figure 5J). The rapid decrease of EGFR protein
level likely reflects both decreased transcription of mutant EGFR
and the significant reduction in the number of mutant EGFR-
expressing tumor cells as shown from histological analyses
(Figure 5B). These data demonstrate that a marked reduction
of tumor cell proliferation and increase in tumor cell apoptosis
is associated with deprivation of hEGFR mutant expression,
demonstrating the requirement of hEGFR mutant expression
for tumor maintenance.
The hEGFR mutant-driven lung tumors are sensitive
to treatment with erlotinib or HKI-272 as well as a
prolonged course of cetuximab treatment
To investigate the sensitivity of these hEGFR kinase domainmu-
tant-driven lung tumors to different EGFR-targeted therapies,
we serially imaged the tumor-bearing bitransgenic mice before
and after treatment with either erlotinib, a reversible EGFR inhib-
itor, or HKI-272, an irreversible EGFR inhibitor (Kwak et al., 2005;
Rabindran et al., 2004). After 8 weeks of doxycycline treatment,
bitransgenic CCSP-rtTA/Tet-op-hEGFR L858R-Luc and CCSP-
rtTA/Tet-op-hEGFR Del-Luc mice were imaged with MRI to
document the baseline tumor burden. Tumor-bearing mice
were then treated orally with erlotinib (6 mice from both Del
and L858R lines), HKI-272 (4 mice from Del and 5 from L858R
lines), or placebo (3 mice per line). Both compounds were given
by gavage at a dose of 50 mg/kg for 1 week, and all mice were489
A R T I C L EFigure 4. Radiographical analyses of the essential roles of hEGFR kinase domain mutants for tumor maintenance
A: Bitransgenic CCSP-rtTA/Tet-op-hEGFR L858R-Luc or CCSP-rtTA/Tet-op-hEGFR Del-Luc mice were given a doxycycline diet for 8 weeks, which was then
replaced with a normal diet for 1 week.
B: For long-term doxycycline withdrawal experiments, the three bitransgenic CCSP-rtTA/Tet-op-hEGFR Del-Luc mice were given doxycycline diet for 9 week,
which was then replaced with a normal diet for a long period.
All mice were MRI imaged before and after doxycycline withdrawal at indicated time points. Hearts are indicated as H. Bar diagram expressed as mean 6
standard deviation illustrates the tumor regression measured by MRI, and statistical analyses were performed using Student’s exact t test.kept on doxycycline throughout the study. After 1 week of treat-
ment, bitransgenicmice fromboth L858R andDel lines receiving
either erlotinib or HKI-272 demonstrated a significant tumor bur-
den reduction (81% 6 7% for erlotinib and 85% 6 8% for HKI-
272) as documented by restaging MRI (Figure 6). These data
demonstrate that inhibition of EGFRactivity using TKIs is a highly
effective therapy in these tumors, since the hEGFR kinase do-
main mutants are directly involved in the tumor initiation, cell
survival, and tumor maintenance.
Cetuximab is a humanized monoclonal antibody designed to
interfere with the binding of EGF or other ligands to the extracel-
lular domain of EGFR (Giaccone, 2005; Hynes and Lane, 2005;
Minna et al., 2005). In order to determine the efficacy of cetuxi-
mabmonotherapy in an in vivomodel, we treated tumor-bearing
bitransgenic mice (4 mice from L858R line) with 1.0 mg cetuxi-
mab by intraperitoneal (I.P.) injection every two days. After 1
week of treatment, these mice underwent reimaging and were
sacrificed for histological analysis. The targeting of cetuximab
in the lung tumors driven by hEGFR kinase domain mutant ex-
pression was confirmed by positive fluorescence immunostain-
ing using anti-human IgG-FITC in comparison with the negative
staining in those tumors treated with placebo (data not shown).
In contrast to HKI-272-treated or erlotinib-treated mice, cetuxi-
mab therapy was less effective (46% 6 23%) than erlotinib as
measured by MRI imaging after 1 week of treatment (Figure 6).
Histological analyses of the lungs from the mice treated with
erlotinib or HKI-272 for 1week confirmed the dramatic reduction
of tumor burden seen in the imaging scans (Figure 7A). Further-
more, in contrast to the group treated with cetuximab for 1
week, the lungs treated with erlotinib or HKI-272 were grossly490normal and microscopically similar to that seen in the mice after
doxycycline withdrawal (Figure 7A and data not shown). In the
areas likely representing the remnants of tumors treated with
either erlotinib or HKI-272, a significantly lower number of Ki-
67-positive cells were visible compared with tumors from cetux-
imab-treated mice (Figures 7A and 7B). Positive TUNEL staining
was also notable in remnant tumor areas, suggesting that the
treatment of either erlotinib or HKI-272 results in tumor resolu-
tion associated with an apoptotic process (Figures 7A and
7C). In contrast, the tumors treated with cetuximab for 1 week
retained similar pathologic features to those from untreated an-
imals showing high Ki-67 staining and low TUNEL staining. In
accord with these findings, treatment with erlotinib or HKI-272
for 1 week decreased both the total EGFR and activated
EGFR levels in the lungs similar to those observed after doxycy-
cline withdrawal, whereas the effects of 1 week of cetuximab
treatment on total and activated EGFR were considerably
more modest (Figure 7D). Thus, these data demonstrate that
pharmacologically effective EGFR inhibition leads to rapid tu-
mor regression associated with decreased tumor proliferation
and increased apoptosis of tumor cells.
As 1 week of cetuximab treatment was not as effective as er-
lotinib or HKI-272, we sought to determine the relative efficacy
of these agents to longer-term treatment. To this end, we per-
formed the treatment using either erlotinib or cetuximab for 4
weeks (3mice each from L858R line). Interestingly, after 2weeks
of cetuximab treatment, we began to observe a larger decrease
of tumor burden (75% 6 5%), and after 4 weeks of treatment,
a progressive 94% 6 4% shrinkage of the tumors, comparable
to the durable tumor response seen with 4 weeks of erlotinibCANCER CELL JUNE 2006
A R T I C L EFigure 5. Molecular and histopathological analysis of the essential roles of hEGFR kinase domain mutants for tumor maintenance
A–C: BitransgenicCCSP-rtTA/Tet-op-hEGFR L858R-Luc orCCSP-rtTA/Tet-op-hEGFR Del-Luc mice with lung tumors documented by MRI imaging were analyzed
by histopathologic examination before (A) and 1 week (B) and 3 weeks (C) after doxycycline withdrawal.
D–G: In contrast to those tumors under continuous doxycycline treatment (D, Ki-67 staining and F, TUNEL staining), dramatically decreased Ki-67-positive cells (E)
and increased TUNEL-positive cells (G), indicated by arrows, are present in lung tumors from the bitransgenic mice after one week of doxycycline withdrawal.
Hand I: Bar diagrams expressed as mean6 standard deviation illustrating the proliferative (H) and apoptotic (I) indices in lung tumors before and 1 week after
doxycycline withdrawal were determined from at least 200 high-power fields (HPF). Statistical analyses were preformed using Student’s exact t test.
J: Protein levels of total EGFR and phospho-EGFR Y1068 were analyzed by immunoblotting. b-actin served as loading control. Data shown are representative
of three independent experiments.treatments (Figure 8). These data suggest that although 1 week
of cetuximab treatment is not as efficient as small TKI treatment,
with a prolonged treatment, the efficacy of cetuximab is compa-
rable to that of erlotinib treatment.
Discussion
We have demonstrated that the two common hEGFR kinase do-
main mutants are oncogenic in vivo and that their expression is
essential for tumor initiation, survival, and maintenance, validat-
ing these hEGFR kinase domain mutants as therapeutic targets
for cancer therapy. Similar results have been obtained by an-
other group that also generated inducible bitransgenic mice
expressing the humanEGFR kinase domainmutants specifically
in the lungs (Politi et al., 2006).
Consistent with both in vitro human NSCLC cell lines and clin-
ical studies, the mouse lung tumors driven by overexpression of
hEGFR kinase domain mutants are very sensitive to either erlo-
tinib or HKI-272 EGFR-targeted therapy in both short-term and
long-term treatment. In contrast, short-term (1 week) treatment
with cetuximab was less effective, although the prolonged treat-
ment (4 weeks) did prove to be effective as well. Tumor regres-
sion caused by EGFR inhibitor treatment is associated with pro-
liferative arrest and apoptosis. These results are consistent with
the dramatic clinical responses to erlotinib or gefitinib treatmentCANCER CELL JUNE 2006in NSCLC patients bearing tumors with these hEGFR kinase
domain mutations.
Mutations of the hEGFR kinase domain usually occur in two re-
gions of EGFR: exon 19 deletion of the amino acid sequence
LREA and the exon 21 point mutation L858R. Initial studies dem-
onstrated that these two hEGFRmutants are more potent stimu-
lators of the phosphoinositide-3 kinase (PI3K)/Akt survival signal-
ing than wt hEGFR (Sordella et al., 2004). However, several other
studies suggested that the exon 19 deletionmutant may function
differently from L858R (Pao et al., 2004). When overexpressed in
293T cells, the hEGFR exon 19 deletion mutant had less auto-
phosphorylationactivity thaneither thewtEGFRorL858Rmutant
(Pao et al., 2004). Unlike the L858R mutant, the exon 19 deletion
mutant had similar sensitivity to gefitinib as wt EGFR in these
studies (Pao et al., 2004). The different findings observed be-
tween these sets of studies may reflect the use of different cell
lines, each with a distinct complement of ErbB family members,
for the various experiments (Janne et al., 2005; Pao et al., 2004;
Sordella et al., 2004). Interestingly, there are emerging clinical
data suggesting that lungcancer patientswhose tumor harbored
theEGFR exon 19 deletion andwhowere treatedwith erlotinib or
gefitinib had a longer median survival than erlotinib- or gefitinib-
treated patientswith theEGFR L858Rpointmutation (Riely et al.,
2006). In our study, we have demonstrated that both the exon 19
deletion mutant and the L858R mutant are equally transforming
in vivowithout notablephenotypic difference, asboth caused the491
A R T I C L EFigure 6. Differential response of lung tumors
driven by hEGFR kinase domain mutant expres-
sion to 1-week treatment with erlotinib, HKI-272,
or cetuximab
Bitransgenic CCSP-rtTA/Tet-op-hEGFR L858R-Luc
or CCSP-rtTA/Tet-op-hEGFR Del-Luc mice were
orally treated with either erlotinib or HKI-272 at
50 mg/kg daily or cetuximab I.P. at 1 mg per
dose every two days. These mice were MRI im-
aged before and after 1 week of treatment.
Empty vehicle was used as control. Representa-
tive imaging were shown from L858R line. Hearts
are indicated as H. Bar diagram expressed as
mean 6 standard deviation illustrates the tumor
regression measured by MRI, and statistical anal-
yses were performed using Student’s exact t test.development of lung adenocarcinomas with BAC features in
a similar time period with similar histology. Furthermore, in our
mouse models, no notable differences were observed between
these two mutants in their abilities to activate EGFR signaling,
to initiate malignant transformation, or to confer sensitivity of tu-
mors to short-term erlotinib orHKI-272 treatment. As highlighted
by the in vitro studies, the presence of other ErbB family mem-
bers may influence the efficacy of EGFR inhibition (Cappuzzo
et al., 2005b; Engelman et al., 2005; Hirata et al., 2005). Addi-
tional studies are needed to determine the role of ErbB2 and
ErbB3 inourmurinemodels in lung tumorigenesis and inpossible
differential responses of the two hEGFR kinase domain muta-
tions to long-term EGFR inhibition treatment.
EGFR-targeted therapies in lung tumors with overexpression
of hEGFR kinase domain mutants are very effective in mice,
consistent with the human clinical observation thatmost NSCLC
patients with hEGFR kinase domain mutations respond to either
erlotinib or gefitinib. Our mouse model data suggest that the
lung tumors harboring hEGFR kinase domain mutations are de-
pendent on the activated EGFR signaling for survival and thus
provide a biological explanation for marked tumor responses
caused by inhibition of this pathway. However, the EGFR kinase
domain mutations are present in only 10% of lung adenocarci-
nomas in Caucasians and 30% of East Asian patients (Pao
and Miller, 2005; Shigematsu et al., 2005a). There also appear
to be NSCLC patients with wt EGFR who clinically benefit
from gefitinib and erlotinib therapy by stabilizing disease and
preventing further progression (Engelman and Janne, 2005;
Giaccone, 2005). In vitro studies have suggested that expres-
sion of wt hEGFR in NSCLC might not play a prominent role in
malignant transformation or survival pathways, but instead be
involved in cell proliferation pathways (Adjei, 2005; Sordella
et al., 2004). Consistent with these in vitro observations, thus
far, we have failed to observe lung tumor development in 2
founders (more than 6 mice per founder cohort) with overex-
pression of wt hEGFR in lung compartments after 26 weeks of492doxycycline administration (data not shown). It remains possible
that lung tumors might develop with a much longer latency pe-
riod and/or that other concurrent genetic alterations involving
p53 or PTEN are necessary for these wt EGFR-overexpressing
mice to develop lung cancer.
HKI-272 is an irreversible inhibitor that covalently binds to the
EGFR kinase domain cleft, whereas erlotinib and gefitinib are re-
versible EGFR inhibitors. Almost all NSCLC patients whose tu-
mors harbor hEGFR kinase domain mutations initially respond
to gefitinib or erlotinib, but eventually acquire resistance to these
inhibitors. Molecular analyses of some of the relapsed tumors
have shown a secondary hEGFR T790M mutation (Kobayashi
et al., 2005a; Kwak et al., 2005; Pao et al., 2005a). HKI-272 in vi-
tro is able to overcome that resistance (Kwak et al., 2005). Re-
cently, we have also shown that HKI-272 is effective in treatment
of EGFRvIII-dependent mouse lung tumors; EGFRvIII, a well
characterized activating EGFR mutation harboring an in-frame
deletion of exon 2 to 7, was found to be present in a small per-
centage of human squamous cell lung cancers (Ji et al., 2006).
Here, we demonstrate that HKI-272 is as effective as erlotinib
in the treatment of tumors driven by expression of two major
groups of hEGFR kinase domain mutants. It would be of interest
to determine the potential efficacy of HKI-272 relative to erlotinib
and gefitinib in patients who have not been exposed to EGFR
inhibitors and whether or not a different spectrum of resistance
mutations would develop after chronic treatment with either
class of EGFR inhibitors or in combination.
Our results with cetuximab treatment in mice lung cancers
driven by overexpression of hEGFR kinase domain mutants dif-
fer somewhat from recent publications of EGFRmutant cell lines
studies in vitro (Mukohara et al., 2005). The in vitro studies sug-
gest that cetuximab was less effective than gefitinib at inhibiting
the growth of EGFR mutant cell lines. These studies were per-
formed over a 72 hr exposure period, and in fact are similar to
the short term (1 week) in vivo cetuximab treatment in the lung
tumors bearing EGFR kinase domain mutants in mice. TheCANCER CELL JUNE 2006
A R T I C L EFigure 7. Histopathological and molecular analyses of the lung tumors after 1 week of treatment with erlotinib, HKI-272, or cetuximab
A: Bitransgenic mice bearing lung tumors treated with either erlotinib or HKI-272 or cetuximab as documented by MRI scan were further analyzed histolog-
ically. Tumors from mice treated with either erlotinib or HKI-272 had dramatic decrease of interstitial thickness and cellularity, consistent with tumor regression
detected by the MRI analysis. These findings are associated with a decrease in Ki-67-positive tumor cells and an increase in TUNEL-positive staining as indicated
by arrows, in contrast to the lung tumors treated with cetuximab.
B and C: Bar diagrams expressed as mean 6 standard deviation illustrating the proliferative (B) and apoptotic (C) indices in lung tumors before and after 1
week of treatment with erlotinib, HKI-272, or cetuximab, determined from at least 200 high-power fields (HPF).
D: Immunoblotting analysis showed decreased levels of both total EGFR and phosphor-EGFR Y1068 in the lungs from the bitransgenic mice treated for 1 week
with either erlotinib or HKI-272, but not cetuximab. b-actin served as loading control. Data shown are representative of at least 3 independent experiments.
Representative data were shown from the L858R line.prolonged exposures of cetuximab were not examined in in vitro
cell line studies. Interestingly, our study of prolonged cetuximab
treatment in vivo (>2 weeks) demonstrates that cetuximab is
effective in treatment of lung tumors driven by hEGFR mutant
overexpression as well (Figure 8). This difference in the time
course of tumor response between cetuximab and TKIs from
in vivo studies might be explained in several ways, including
that cetuximab is a less effective inhibitor of EGFR mutant sig-
naling or that the large molecular weight of cetuximab requires
a longer period to reach inhibitory levels in tumor tissues.
In summary, we have generated an informative model of hu-
man lung adenocarcinomas harboring the hEGFR kinase do-
main mutations that predict clinical response to EGFR-targeted
therapies. We have shown that expression of hEGFR mutants is
essential for tumor maintenance in these lung cancers and that
small molecule EGFR inhibitors and the humanized anti-EGFR
antibodies demonstrate activity in this model, albeit with differ-
ent kinetics. These unique lung cancer mouse models will be
useful for future testing to determine the mechanism of tumor
regression caused by EGFR inhibition and to determine the po-
tency of newer-generation EGFR inhibitors or other novel thera-
peutics prior to human clinical testing. In addition, these mouse
models will serve as platforms onwhich to layer additional onco-
genic or tumor suppressor alleles to determine their geneticCANCER CELL JUNE 2006interactions on tumor initiation and progression, as well as their
impact on sensitivities to therapeutic interventions.
Experimental procedures
Mouse cohorts
The generation of Tet-op-hEGFR L858R-Luc andCCSP-rtTA/Tet-op-hEGFR
Del-Luc mice is described in the Supplemental Data. Three founders from
L858R (#12, #14, and #27) and 2 founders from Del (#19 and #23) with tight
regulation of hEGFR mutant expression were identified as described in the
Supplemental Data for further studies.
The CCSP-rtTA mice were generously provided by Dr. Jeffery Whitsett at
University of Cincinnati (Fisher et al., 2001). All mice were housed in a patho-
gen-free environment at theDana-Farber Cancer Institute. All mice were han-
dled in strict accord with good animal practice as defined by the Office of
Laboratory Animal Welfare, and all animal work was done with DFCI IACUC
approval. Genotyping protocols are supplied in the Supplemental Data.
Histology and immunohistochemistry
Mice were sacrificed and the left lungs were dissected and snap-frozen for
biochemical analysis. The remainder of the lungs were then inflated with neu-
tral buffered 10% formalin for 10min and then fixed in 10% formalin overnight
at room temperature, washed once in PBS and put in 70% ethanol, embed-
ded in paraffin, and sectioned at 5 mm. Hematoxylin and eosin (H&E) stains
were performed in the Department of Pathology in Brigham and Women’s
Hospital. Details for immunohistochemistry and antibody information are
listed in the Supplemental Data.493
A R T I C L EDoxycycline withdrawal and targeted therapy using the hEGFR
inhibitors erlotinib, HK-272, or cetuximab in vivo
After sustained doxycycline treatment, the bitransgenic mice were subjected
to MRI imaging to document the lung tumor burden. For doxycycline with-
drawal experiment, the mice were given normal diet and MRI reimaged at in-
dicated time points. For targeted therapies, either erlotinib (Biaffin GmbH &
Co. KG, Kassel, Germany) or HKI-272 (Wyeth Pharmaceuticals, Pearl River,
NY) formulated in 0.5% methocellulose-0.4% polysorbate-80 (Tween 80,
Sigma-Aldrich) was given to mice by gavage at 50 mg/kg daily. Cetuximab
(BMS pharmaceuticals, NJ) was given by I.P. injection into mice at 1 mg
per dose every two days. After treatment, the same mice were MRI imaged
at different time points to determine the tumor volume reduction. The mice
were sacrificed and subjected to histological and biochemical analysis.
RT-PCR and quantitative PCR
Total RNA samples were prepared as described (Tonon et al., 2005) and ret-
rotranscribed into first-strand cDNA using the first-strand synthesis system
following the manufacturer’s protocol (Invitrogen, Carlsbad, CA). Quantita-
tive PCR was performed in an ABI 7700 sequence detection system (Perkin
Elmer Life Sciences, Shelton, CT). Additional details are supplied in the Sup-
plemental Data.
Western blot analysis
The lungswerehomogenized inRIPAbuffer containingprotease inhibitor cock-
tail and phosphatase inhibitors (EMD Biosciences, San Diego, CA) and sub-
jected toWestern blot. Antibody information is listed in theSupplemental Data.
MRI imaging and tumor volume measurement
MRI measurements were performed as described in the Supplemental Data.
Using the RARE sequence scans, volume measurements of the tumors were
preformed using in-house custom software, and statistical analysis was per-
formed using Student’s exact t test (Sun et al., 2004).
Figure 8. Prolonged treatment of lung tumors driven by hEGFR kinase do-
main mutant expression using either cetuximab or erlotinib
Bitransgenic CCSP-rtTA/Tet-op-hEGFR L858R-Luc mice (3 per group) were
treated with either erlotinib orally at 50 mg/kg daily or cetuximab I.P. injec-
tion at 1 mg every two days for 4 weeks. These mice were MRI imaged
before and after 2-week and 4-week treatment. Hearts are indicated as
H. Bar diagram expressed as mean 6 standard deviation illustrates the
tumor regression measured by MRI, and statistical analyses were performed
using Student’s exact t test.494Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and
two supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/9/6/485/DC1/.
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